摘要
以氟尿嘧啶为基础的同步放化疗后手术为局部进展期直肠癌的标准治疗模式。虽然与单纯手术相比,其局部复发率有所降低,但约1/3的患者会发生远处转移,这成为该治疗模式最主要的失败原因。为了减少远处转移,提高患者的生存率,伊立替康因其能与放疗产生协同效应的作用机制越来越受到研究者的关注。近年有关伊立替康在局部晚期直肠癌新辅助治疗中的探索也越来越多。全文旨在回顾与展望伊立替康在局部进展期直肠癌新辅助放化疗中的应用。
Preoperative 5-FU based chemoradiotherapy(CRT)followed by surgery is the standard treatment for local advanced rectal cancer(LARC).Although this pattern has a lower local recurrence(LR)rate compared with surgery alone,about 1/3 patients will suffer from distant metastases,which is the main reason of treatment failure.In order to eliminate the distant metastases and prolong survival times,irinotecan has been paid more and more attention due to its potential synergistic effect with irradiation.Therefore,there are an increasing number of clincial and exploratory trials about irinotecan in neoadjuvant CRT in LARC recently.Here we aim to review the application of irinotecan in n CRT in patients with LARC.
作者
黄成溢
朱骥
HUANG Cheng-yi;ZHU Ji(The Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital),Institute of Basic Medicine and Cancer(IBMC),Chinese Academy of Sciences,Hangzhou 310022,China;Zhejiang Key Laboratory of Radiation Oncology,Hangzhou 310022,China;Wenzhou Medical University,Wenzhou 325035,China)
出处
《肿瘤学杂志》
CAS
2021年第10期791-797,共7页
Journal of Chinese Oncology
